Navigation Links
NEWSWEEK Cover: The Hunt for an Addiction Vaccine
Date:2/24/2008

Emerging Treatments for Addiction are Treating the Disease as Chronic,

Relapsing Brain Disorder Advances Made in Understanding Biology of Addiction 'and That is Finally

Starting to Push the Thinking From 'Moral Failing,' to 'Legitimate

Illness,' Says Addiction Expert

NEW YORK, Feb. 24 /PRNewswire/ -- Although the American Medical Association recognized addiction as a disease back in 1956, only now are we beginning to see treatments that target the underlying biochemistry of that disease, Newsweek reports in the March 3 cover, "The Hunt for an Addiction Vaccine" (on newsstands Monday February 25). Health Reporter Jeneen Interlandi reports that this emerging paradigm treats addiction as a chronic, relapsing brain disorder to be managed with all the tools at medicine's disposal. The addict's brain is malfunctioning, as surely as the pancreas in someone with diabetes. In both cases, "lifestyle choices" may be contributing factors, but no one regards that as a reason to withhold insulin from a diabetic. "We are making unprecedented advances in understanding the biology of addiction," says David Rosenblum, a public-health professor and addiction expert at Boston University. "And that is finally starting to push the thinking from 'moral failing' to 'legitimate illness'."

(Photo: http://www.newscom.com/cgi-bin/prnh/20080224/NYSU004 )

Interlandi examines the science that is helping to understand how the addicted brain functions and the compounds being developed or tested by the National Institute on Drug Abuse (NIDA) that block the intoxicating effects of drugs, including vaccines that train the body's own immune system to bar them from the brain. To the extent that "willpower" is a meaningful concept at all, the era of willpower-in-a-pill may be just over the horizon. "The future is clear," says Nora Volkow,
'/>"/>

SOURCE Newsweek
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine news :

1. NEWSWEEK: Media Lead Sheet/February 4, 2008 Issue (on newsstands Monday, January 28)
2. NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21).
3. NEWSWEEK: Media Lead Sheet/January 21, 2008 Issue (on newsstands Monday, January 14)
4. NEWSWEEK: International Editions: Highlights and Exclusives, Dec. 31, 2007- Jan. 7, 2008
5. NEWSWEEK: International Editions: Highlights and Exclusives, December 10, 2007 Issue
6. NEWSWEEK: Cover: Health for Life: Fertility & Diet
7. NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26).
8. NEWSWEEK: Media Lead Sheet/November 19, 2007 Issue (on newsstands Monday, November 12)
9. NEWSWEEK: Media Lead Sheet/November 5, 2007 Issue (on newsstands Monday, October 29).
10. NEWSWEEK: Cover: Kids and the Growing Food Allergy Threat
11. NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... Conserve hip replacement lawsuits in U.S. District ... in response to a request from Plaintiffs’ Counsel to ... Defendant. The May 17th Order grants that request, ... be conducted. (In re: Wright Medical Technology, Inc., Conserve ...
(Date:5/21/2013)... MedMar Healing Center announces their participation ... Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and ... The goal is to raise food to help area kids ... families in recent years. , “We like being able ... need,” explains Douglas Chloupek of MedMar Healing Center. “Taking part ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
... risk of certain types of cervical cancer. The study, ... reveals obesity and body fat //distribution are associated more ... study involved 124 women with adenocarcinoma, 139 with squamous ... control group. Adenocarcinomas involve cells from the walls of ...
... Syndrome is a severe injury to most or all of ... and often are on life support. //A new study finds ... ARDS after a trauma. ,ARDS is not a specific ... with a number of diseases including pneumonia, shock, sepsis and ...
... the larynx are diagnosed in the United States. About 5,000 ... taking away their voice box and communication, as they know ... back. ,For five years, five months and 13 days, ... forget, and that is something she says she will never ...
... who had very low birth weights are likely to ... others born at higher birth rates. //The study, conducted ... reports respiratory function is more drastically reduced with smoking ... with low birth weight, defined as weighing less than ...
... prevent bone loss may also help prevent prostate cancer from ... Kingdom indicates oral sodium clodronate may slow the spread of ... //This is a drug commonly used to prevent bone loss. ... about 85 percent of men. The researchers recruited 311 men ...
... Unlike the outbreak earlier this year, the next time ... public health systems, //says a report by the National ... chains of SARS transmission of were stopped, the virus ... to humans, the report says. ,"The wave of ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Return of SARS possible this fall 2
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 25G x 5/8in (.50 x 16mm)...
... Unique product designed for LASIK surgery ... Designed to irrigate the corneal interface ... easy insertion under the flap and ... ports provide multi-directional irrigation.27G x 7/8in ...
Medicine Products: